Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves
anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Celldex Therapeutics The Foundation for Barnes-Jewish Hospital